233 related articles for article (PubMed ID: 28062704)
1. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.
Dillon MT; Barker HE; Pedersen M; Hafsi H; Bhide SA; Newbold KL; Nutting CM; McLaughlin M; Harrington KJ
Mol Cancer Ther; 2017 Jan; 16(1):25-34. PubMed ID: 28062704
[TBL] [Abstract][Full Text] [Related]
2. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
4. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
6. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
[TBL] [Abstract][Full Text] [Related]
7. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine
Wallez Y; Dunlop CR; Johnson TI; Koh SB; Fornari C; Yates JWT; Bernaldo de Quirós Fernández S; Lau A; Richards FM; Jodrell DI
Mol Cancer Ther; 2018 Aug; 17(8):1670-1682. PubMed ID: 29891488
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
10. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
11. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091
[TBL] [Abstract][Full Text] [Related]
12. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.
Dunne V; Ghita M; Small DM; Coffey CBM; Weldon S; Taggart CC; Osman SO; McGarry CK; Prise KM; Hanna GG; Butterworth KT
Radiother Oncol; 2017 Sep; 124(3):475-481. PubMed ID: 28697853
[TBL] [Abstract][Full Text] [Related]
14. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
15. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ
Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034
[TBL] [Abstract][Full Text] [Related]
16. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
[TBL] [Abstract][Full Text] [Related]
17. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
[TBL] [Abstract][Full Text] [Related]
18. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
20. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
